CAJ | 학술논문

目的：探讨调强放疗（IMRT）联合同期多西他赛加顺铂化疗治疗局部晚期非小细胞肺癌（NSCLC）的疗效。方法：将2012年1月～2014年12月收治的晚期NSCLC患者分为实验组（60例）和对照组（60例），实验组采用IMRT联合同期多西他赛加顺铂化疗治疗，对照组采用三维适形放疗联合同期多西他赛加顺铂化疗治疗。统计两组的疗效、不良反应情况、生活改善程度，利用卡方检验分析相关数据。结果：实验组的有效率和一年生存率分别为76.67%和78.33%，明显高于对照组的60.00%和56.67%（P＜0.05）。实验组发生放射性食管炎和放射性肺炎的概率明显低于对照组（P＜0.05）。治疗后，实验组生活质量良好的患者占68.33%，比对照组（56.67%）高出11.66%。结论：IMRT联合同期多西他赛加顺铂化疗治疗局部晚期NSCLC的疗效明确，可以提高一年生存率减少不良反应。
목적：탐토조강방료（IMRT）연합동기다서타새가순박화료치료국부만기비소세포폐암（NSCLC）적료효。방법：장2012년1월～2014년12월수치적만기NSCLC환자분위실험조（60례）화대조조（60례），실험조채용IMRT연합동기다서타새가순박화료치료，대조조채용삼유괄형방료연합동기다서타새가순박화료치료。통계량조적료효、불량반응정황、생활개선정도，이용잡방검험분석상관수거。결과：실험조적유효솔화일년생존솔분별위76.67%화78.33%，명현고우대조조적60.00%화56.67%（P＜0.05）。실험조발생방사성식관염화방사성폐염적개솔명현저우대조조（P＜0.05）。치료후，실험조생활질량량호적환자점68.33%，비대조조（56.67%）고출11.66%。결론：IMRT연합동기다서타새가순박화료치료국부만기NSCLC적료효명학，가이제고일년생존솔감소불량반응。
Objective: Investigate the curative effect, adverse reaction, and mend matters of patients's life in treatment of locally advanced non-small cell lung cancer (NSCLC) was used by intensity-modulated radiotherapy (IMRT) combined with docetaxel and cisplatin. Methods: The patients of locally advanced NSCLC who receive and cure from January 2012 to December 2014, They were divided into experimental group (60 cases) and control group (40 cases). Therapeutic schedule of experimental group were IMRT combined with docetaxel and cisplatin, and control group were three-dimensional conformal radiotherapy combined with docetaxel and cisplatin. The curative effect, 1-year survival rate, adverse reaction, quality of life were be statisticsed. using chi-square test to analyze the data. Results:The experimental group's response rate and 1-year survival rate were 76.67% and 78.33%, which were all phanero-higher than the control group's 60.00%and 58.33%(P<0.05). The experimental group's incidence of radiation esophagitis and radiation pneumonitis were all phanero-lower than the control group's(P<0.05). The rate of quality of life for good in the experimental group was 68.33%, which higher than control group(56.67%) 11.66%. Conclusions:The therapeutic effect is clear-cut which use IMRT combined with docetaxel and cisplatin to treat locally advanced NSCLC, this therapeutic schedule can improve the 1-year survival rate and reduce the rate of adverse reaction.